SARS-CoV 2: Clinical Trials

6 trials for SARS-CoV 2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Terminated 6
Phase 31Terminated 1

Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash - COVID-19, SARS-CoV 2
Phase 2TerminatedUniversity of California, San Francisco542021-03-312023-11-18
Convalescent Plasma for Early Treatment of COVID-19
Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%) - SARS-CoV 2, COVID-19
Phase 2TerminatedAndrew Eisenberger2232021-03-122024-08-28
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID
Phase 2 / Phase 3TerminatedAPR Applied Pharma Research s.a.1442021-02-152023-02-03
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
GLS-1200, Placebo - SARS-CoV 2, Infection
Phase 2TerminatedGeneOne Life Science, Inc.1842020-06-102025-07-31
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine - COVID-19, SARS-CoV 2
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)202020-05-132021-11-16
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19
CONVALESCENT PLASMA - COVID, SARS-CoV 2
Phase 2TerminatedAzienda Ospedaliero, Universitaria Pisana12020-05-012020-11-12

Narrower conditions

COVID-19 (5)  ·  Coronavirus Infections (2)  ·  Acute Lung Injury (1)  ·  Dyspnea (1)  ·  Infections (1)  ·  Pharyngeal Diseases (1)  ·  Pneumonia (1)  ·  Respiratory Distress Syndrome (1)  ·  Virus Diseases (1)

Broader conditions

Lung Diseases (6)  ·  Respiratory Tract Diseases (6)  ·  Coronaviridae Infections (5)  ·  Nidovirales Infections (5)  ·  Pneumonia, Viral (5)  ·  RNA Virus Infections (5)  ·  Respiratory Tract Infections (5)  ·  Infections (4)  ·  Pneumonia (4)  ·  Virus Diseases (4)  ·  Coronavirus Infections (3)  ·  Lung Injury (1)  ·  Otorhinolaryngologic Diseases (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Respiration Disorders (1)

Interventions

Azithromycin (1)  ·  Cetylpyridinium (1)  ·  Ethanol (1)  ·  Hydrogen Peroxide (1)  ·  Hydroxychloroquine (1)  ·  Water (1)  ·  aviptadil (1)  ·  chlorine dioxide (1)

Sponsors

APR Applied Pharma Research s.a. (1)  ·  Andrew Eisenberger (1)  ·  Azienda Ospedaliero, Universitaria Pisana (1)  ·  GeneOne Life Science, Inc. (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  University of California, San Francisco (1)

Countries

United States (4)  ·  Brazil (1)  ·  Italy (1)

Top investigators

Davey Smith, MD (1)  ·  Francesco Menichetti (1)  ·  Jessica Justman, MD (1)  ·  Jonathan C Javitt, MD, MPH (1)  ·  Stuart A Gansky, DrPH (1)

Results publications

PMID 32219428, PMID 42238425